Skip to main content

GS-US-419-3896 GS-US-419-3896 - A Long Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease

NCT02914600

GS-US-419-3896 - A Long Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease

Associated Conditions

Inflammatory Bowel Disease (IBD)

Principal Investigator

Sponsor

Gilead Sciences

You have been asked to be part of this study because you have been diagnosed with Crohn’s disease, and you have already participated in another Gilead filgotinib treatment study for moderate to severe Crohn’s disease.
The purpose of this study is to see if filgotinib is safe in the long-term treatment of Crohn’s disease and to give you the opportunity to remain on filgotinib treatment.

This study is currently enrolling.